Unknown

Dataset Information

0

Immunotherapy in colorectal cancer: rationale, challenges and potential.


ABSTRACT: Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for multiple types of solid cancers, including a subset of colorectal cancers (CRCs). Two programmed cell death 1 (PD1)-blocking antibodies, pembrolizumab and nivolumab, have shown efficacy in patients with metastatic CRC that is mismatch-repair-deficient and microsatellite instability-high (dMMR-MSI-H), and have been granted accelerated FDA approval. In contrast to most other treatments for metastatic cancer, immunotherapy achieves long-term durable remission in a subset of patients, highlighting the tremendous promise of immunotherapy in treating dMMR-MSI-H metastatic CRC. Here, we review the clinical development of immune checkpoint inhibition in CRC leading to regulatory approvals for the treatment of dMMR-MSI-H CRC. We focus on new advances in expanding the efficacy of immunotherapy to early-stage CRC and CRC that is mismatch-repair-proficient and has low microsatellite instability (pMMR-MSI-L) and discuss emerging approaches for targeting the immune microenvironment, which might complement immune checkpoint inhibition.

SUBMITTER: Ganesh K 

PROVIDER: S-EPMC7295073 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunotherapy in colorectal cancer: rationale, challenges and potential.

Ganesh Karuna K   Stadler Zsofia K ZK   Cercek Andrea A   Mendelsohn Robin B RB   Shia Jinru J   Segal Neil H NH   Diaz Luis A LA  

Nature reviews. Gastroenterology & hepatology 20190601 6


Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for multiple types of solid cancers, including a subset of colorectal cancers (CRCs). Two programmed cell death 1 (PD1)-blocking antibodies, pembrolizumab and nivolumab, have shown efficacy in patients with metastatic CRC that is mismatch-repair-deficient and microsatellite instability-high (dMMR-MSI-H), and have been granted accelerated FDA approval. In contrast to most  ...[more]

Similar Datasets

| S-EPMC10360200 | biostudies-literature
| S-EPMC4968118 | biostudies-literature
| S-EPMC6299311 | biostudies-literature
| S-EPMC6689806 | biostudies-literature
| S-EPMC7383341 | biostudies-literature
| S-EPMC6936245 | biostudies-literature
| S-EPMC9994045 | biostudies-literature
| S-EPMC9220323 | biostudies-literature
| S-EPMC6966558 | biostudies-literature
| S-EPMC6153971 | biostudies-literature